BCL2 and acute myeloid leukemia: Our study, which comprised a representative group of AML patients with cytogenetic and molecular characteristics that conformed to real-world data [29], however, indicates that 1 in 5 AML patients should be considered as BCL-2− and that there is a strong inter-patient heterogeneity, both in terms of BCL-2 staining intensity and frequency, among the BCL-2+ patients.